Practice

Editorial Calls for Monitoring of Low-Dose Methotrexate Users for Adverse Events in Light of New RCT Data

February 26th 2020

By Deana Ferreri, PhD

The use of low-dose methotrexate in rheumatoid arthritis dates back more than 30 years, but despite these decades of clinical use, data on adverse effects have come mostly from observational studies rather than randomized controlled trials (RCTs), the authors say.

2019 Saw Mounting Evidence to Support Nonmedical Switching, Review Article Says

February 21st 2020

By Deana Ferreri, PhD

A recent year-in-review article outlines studies published in 2019 about nonmedical switching from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

What Are the Factors for Starting Anti-TNF Inhibitor Biosimilars in RA and AS?

February 11th 2020

By Deana Ferreri, PhD

The study aimed to provide insight into the real-world patterns of biosimilar initiation in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in Korea by identifying patient characteristics and other factors associated with starting biosimilars using a logistic regression model.

Reference-Based Drug Pricing Shifts Mix of Therapies, Lowers Prices Paid, Study Finds

February 5th 2020

By Allison Inserro

Reference pricing may shift the mix of drugs dispensed from those offering the highest rebates to pharmacy benefit managers to those offering the lowest prices to employers and employees, according to a new study published Wednesday.

Nocebo Effect May Have Role in Some Treatment Failures, Adverse Events in Nonmedical Switching

January 29th 2020

By Deana Ferreri, PhD

Researchers reviewed randomized controlled trials and real-world evidence studies on nonmedical switching; that is, switching patients who are doing well on their current originator therapy to a biosimilar.

Study Suggests CPT-13 Comparable to Infliximab at Lower Cost in Patients With IBD

January 18th 2020

By Deana Ferreri, PhD

The biosimilar CPT-13 (Remsima) is currently approved in Europe for all uses for which the originator infliximab (Remicade) is approved, including Crohn disease (CD) and ulcerative colitis (UC), which are often referred to collectively as IBD.

The Top 5 Biosimilars Articles for the Week of January 6

January 11th 2020

The Center for Biosimilars® recaps the top stories for the week of January 6.

Bio-Thera Solutions' Biosimilar Adalimumab Launches in China

January 10th 2020

By The Center for Biosimilars Staff

It is the first adalimumab biosimilar approved by the China National Medical Products Administration.

Survey Finds Asian Gastroenterologists Report Less Confidence in Biosimilars

January 8th 2020

By Mary Caffrey

Just 6% of the Asian doctors said they felt confident using biosimilars in clinical practice. A survey of European doctors found a similar confidence level in 2013, but that level had climbed to 28.8% by 2015.

Bevacizumab Study Shows Influence of Physician Relationships on Prescribing

January 4th 2020

By The Center for Biosimilars Staff

The findings indicate that interventions that leverage physician relationships may assist with increasing uptake of new, high-value cancer treatments in place of low-value therapies.